The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will help researchers collect more information about how effective the combination
of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous
treatment for their cancer.